Advance Search
JIN Yunzhou. Clinical study of CYP2C9 and VKORC1 gene detection in guiding of warfarin medication after cardiac valve replacement[J]. Journal of Clinical Medicine in Practice, 2022, 26(1): 22-25. DOI: 10.7619/jcmp.20213385
Citation: JIN Yunzhou. Clinical study of CYP2C9 and VKORC1 gene detection in guiding of warfarin medication after cardiac valve replacement[J]. Journal of Clinical Medicine in Practice, 2022, 26(1): 22-25. DOI: 10.7619/jcmp.20213385
shu

Clinical study of CYP2C9 and VKORC1 gene detection in guiding of warfarin medication after cardiac valve replacement

  • Department of Cardiovascular Surgery, Three Gorges Hospital Affiliated to Chongqing University, Chongqing, 404100

More Information
  • Received Date: August 22, 2021
  • Available Online: January 19, 2022
  • Published Date: January 14, 2022
    Graphical Abstract
    • Abstract
  •   Objective  To analyze the standard dose and time of warfarin in patients with different CYP2C9 and VKORC1 genotypes after heart valve surgery, so as to analyze the significance of gene detection in guiding warfarin medication in patients after heart valve surgery.
      Methods  A total of 156 patients who underwent heart valve surgery were randomly selected as study objects, and were divided into four groups according to the test results of CYP2C9 and VKORC1 gene: CYP2C9*3AA group (142 cases), CYP2C9*3 AC group (14 cases), VKORC1 GA/GG group (25 cases) and VKORC1 AA group (131 cases). The age, weight, height, operation method, usage of interference drug, actual standard dose and standard time of different groups were compared.
      Results  The dose of warfarin reaching standard in the CYP2C9*3 AC group was significantly lower than that in the CYP2C9*3AA group (P < 0.05), but there was no significant difference in time of reaching standard between the two groups (P>0.05); the standardized dose of warfarin in the VKORC1 GA/GG group was significantly higher than that in the VKORC1 AA group (P < 0.001), but there was no significant difference in time of reaching standard between the two groups (P>0.05).
      Conclusion  Gene detection of CYP2C9 and VKORC1 is of significance in guiding the use of warfarin in patients after heart valve surgery, which is helpful to guide the selection of initial warfarin dose, but has little influence on the time of reaching the standard.
    • FullText(HTML)
    • References (19)
  • [1]
    许建屏, 石应康, 董力, 等. 中国人心脏瓣膜置换术后低强度抗凝治疗3 000例随访1年报告[J]. 四川大学学报: 医学版, 2016, 47(1): 90-92. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYK201601020.htm
    [2]
    马建新, 董兵, 马建慧, 等. CYP2C9和CYP4F2基因多态性对瓣膜置换术后华法林维持剂量的影响[J]. 实用医学杂志, 2017, 33(7): 1120-1123. doi: 10.3969/j.issn.1006-5725.2017.07.027
    [3]
    CARNICELLI A P, O'GARA P T, GIUGLIANO R P. Anticoagulation after heart valve replacement or transcatheter valve implantation[J]. Am J Cardiol, 2016, 118(9): 1419-1426. doi: 10.1016/j.amjcard.2016.07.048
    [4]
    单广东, 顾翔. 华法林个体化用药影响因素的研究进展[J]. 中华老年多器官疾病杂志, 2021, 20(7): 547-551. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLQG202107020.htm
    [5]
    JOHNSON J A, CAUDLE K E, GONG L, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update[J]. Clin Pharmacol Ther, 2017, 102(3): 397-404. doi: 10.1002/cpt.668
    [6]
    方志远, 丰航, 廉江平, 等. 药物相互作用致华法林药效增强的病例分析[J]. 实用药物与临床, 2017, 20(12): 1422-1426. https://www.cnki.com.cn/Article/CJFDTOTAL-LYLC201712019.htm
    [7]
    D'ANDREAG, D'AMBROSIO R L, DI PERNA P, et al. Apolymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin[J]. Blood, 2005, 105(2): 645-649. doi: 10.1182/blood-2004-06-2111
    [8]
    丁征, 闫婷婷, 芦梦, 等. VKORC1基因分型对华法林初始抗凝治疗的影响和临床指导意义[J]. 药学与临床研究, 2020, 28(2): 113-116. https://www.cnki.com.cn/Article/CJFDTOTAL-YXLY202002009.htm
    [9]
    张阳, 宋沧桑, 王威丽, 等. 基于CYP2C9和VKORC1基因检测指导华法林剂量的临床研究[J]. 中国医院药学杂志, 2020, 40(10): 1140-1144. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ202010016.htm
    [10]
    POKORNEY S D, SIMON D N, THOMAS L, et al. Stability of international normalized ratios in patients taking long-term warfarin therapy[J]. JAMA, 2016, 316(6): 661-663. doi: 10.1001/jama.2016.9356
    [11]
    TOULON P. Developmental hemostasis: laboratory and clinical implications[J]. Int J Lab Hematol, 2016, 38(Suppl 1): 66-77.
    [12]
    WATTANACHAI N, KAEWMOONGKUN S, PUSSADHAMMA B, et al. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients[J]. Eur J Clin Pharmacol, 2017, 73(8): 973-980. doi: 10.1007/s00228-017-2265-8
    [13]
    ZHANG J, CHEN Z, CHEN C. Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: a systematic review and meta-analysis[J]. Meta Gene, 2016, 9: 197-209. doi: 10.1016/j.mgene.2016.07.002
    [14]
    ZHANG Y, ZHENG Z, LIANG X, et al. Effect of amiodarone on the warfarin in different CYP2C9 and VKORC1 status of 207 inpatients[J]. Pharm Sci, 2014, 23(3): 190-193.
    [15]
    LEONARD C E, BRENSINGER C M, BILKER W B, et al. Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics[J]. Int J Cardiol, 2017, 228: 761-770. doi: 10.1016/j.ijcard.2016.11.245
    [16]
    NATHISUWAN S, DILOKTHORNSAKUL P, CHAIYAKUNAPRUK N, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis[J]. Chest, 2011, 139(5): 1130-1139. doi: 10.1378/chest.10-0777
    [17]
    PANCHENKO E, KROPACHEVA E, DOBROVOLSKY A, et al. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients[J]. Pharmacogenomics J, 2020, 20(5): 687-694. doi: 10.1038/s41397-020-0157-2
    [18]
    高伟祺, 李志宏, 陈维红. 2种基于"基因检测指导个体化用药"的华法林剂量预测模型的预测能力比较[J]. 中国临床药学杂志, 2019, 28(1): 22-27. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZZ201901006.htm
    [19]
    KLEIN T E, AHMAN R B, ERIKSSON N, et al. Estimation of the warfarin dose with clinical and pharmaeogenetic data[J]. N Engl J Med, 2009, 360(8): 753. doi: 10.1056/NEJMoa0809329
    • Related Articles

  • Cited by

    Periodical cited type(4)

    1. 邢蓓蓓，申红，王巍，刘璞娟. 基于基因多态性的华法林个体化给药对老年心脏瓣膜置换术后并发症发生率的影响. 河北医科大学学报. 2025(01): 20-24 .
    2. 张超，韩冬，范迪堃，高建朝，杨侃. 血清脂联素、成纤维生长因子-23在心脏瓣膜置换术患者预后中的评估价值. 实用临床医药杂志. 2024(03): 58-62 . 本站查看
    3. 任亚丽，殷晓芹. CYP2C9和VKORC1基因多态性对脑梗死患者华法林个体化的用药指导. 名医. 2024(02): 171-173 .
    4. 武元竹，刘俊，杨魁，李龙，叶明琪，袁梦，栾家杰，韦俊，张大发. 皖南地区汉族人群华法林稳定剂量模型预测准确性的评价与建立. 中国医院药学杂志. 2022(23): 2520-2524 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML
    Article views (292) PDF downloads (9) Cited by(6)
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return